Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.611549/full |
| _version_ | 1818558786491645952 |
|---|---|
| author | S. Morteza Seyed Jafari Laurence Feldmeyer Simon Bossart Dagmar Simon Christoph Schlapbach Luca Borradori |
| author_facet | S. Morteza Seyed Jafari Laurence Feldmeyer Simon Bossart Dagmar Simon Christoph Schlapbach Luca Borradori |
| author_sort | S. Morteza Seyed Jafari |
| collection | DOAJ |
| description | Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab. |
| first_indexed | 2024-12-14T00:16:49Z |
| format | Article |
| id | doaj.art-349ff6b3fdc6461e90808f2d2c70e839 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-14T00:16:49Z |
| publishDate | 2021-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-349ff6b3fdc6461e90808f2d2c70e8392022-12-21T23:25:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-01-011110.3389/fimmu.2020.611549611549Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous PemphigoidS. Morteza Seyed JafariLaurence FeldmeyerSimon BossartDagmar SimonChristoph SchlapbachLuca BorradoriBullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.https://www.frontiersin.org/articles/10.3389/fimmu.2020.611549/fullbullous pemphigoiddupilumabomalizumabrecalcitranttreatment |
| spellingShingle | S. Morteza Seyed Jafari Laurence Feldmeyer Simon Bossart Dagmar Simon Christoph Schlapbach Luca Borradori Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid Frontiers in Immunology bullous pemphigoid dupilumab omalizumab recalcitrant treatment |
| title | Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid |
| title_full | Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid |
| title_fullStr | Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid |
| title_full_unstemmed | Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid |
| title_short | Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid |
| title_sort | case report combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid |
| topic | bullous pemphigoid dupilumab omalizumab recalcitrant treatment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2020.611549/full |
| work_keys_str_mv | AT smortezaseyedjafari casereportcombinationofomalizumabanddupilumabforrecalcitrantbullouspemphigoid AT laurencefeldmeyer casereportcombinationofomalizumabanddupilumabforrecalcitrantbullouspemphigoid AT simonbossart casereportcombinationofomalizumabanddupilumabforrecalcitrantbullouspemphigoid AT dagmarsimon casereportcombinationofomalizumabanddupilumabforrecalcitrantbullouspemphigoid AT christophschlapbach casereportcombinationofomalizumabanddupilumabforrecalcitrantbullouspemphigoid AT lucaborradori casereportcombinationofomalizumabanddupilumabforrecalcitrantbullouspemphigoid |